Insider Selling: Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells 42,797 Shares of Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 42,797 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the completion of the transaction, the insider owned 25,249 shares in the company, valued at approximately $843,064.11. The trade was a 62.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

David Krempa also recently made the following trade(s):

• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.49, for a total transaction of $1,181,630.76.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13.

Eton Pharmaceuticals Stock Up 3.5%

ETON traded up $1.11 during midday trading on Wednesday, hitting $32.40. The company had a trading volume of 442,334 shares, compared to its average volume of 358,595. Eton Pharmaceuticals, Inc. has a 52 week low of $13.09 and a 52 week high of $35.66. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $887.50 million, a price-to-earnings ratio of -462.79 and a beta of 0.82. The stock’s 50 day moving average price is $26.33 and its 200 day moving average price is $19.94.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The company had revenue of $24.27 million during the quarter, compared to the consensus estimate of $22.31 million. On average, research analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Quarry LP acquired a new stake in shares of Eton Pharmaceuticals in the 3rd quarter worth about $37,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth about $44,000. Legal & General Group Plc acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter worth about $41,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth about $74,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth about $109,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Analyst Ratings Changes

ETON has been the subject of several research analyst reports. B. Riley Financial lifted their price target on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, March 20th. HC Wainwright lifted their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Wall Street Zen raised shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $41.00.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.